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peritoneal contamination is likely to have contributed to a
failure to achieve optimal cytoreduction in the case
presented.
The role of adjuvant therapy in the management of
ovarian squamous cell carcinomas is similarly unclear.
Limited experience suggests that surgical management with
close follow up alone would suffice for early stage 1A
disease.7 Stages 1C and above have been targeted with a
variety of adjuvant regimens with variable outcomes.
Relatively poor disease control has been noted with the
conventional regimens to treat epithelial ovarian cancers, i.e
cisplatin, vincristine, mitomycin C, and bleomycin
(POMB).9 On the other hand remarkable responses have
been achieved with paclitaxel based regimens in some
cases.9,10
Radiotherapy has also been used with the rationale
of squamous cell carcinoma being a radiosensitive tumour;
and has brought forth variable results for cancers within
antecedent dermoids.1,8 In the latest case series and review
of literature1, albeit in cases of squamous cell cancers
arising in mature cystic teratoma of the ovary, whole-pelvis
radiation and concurrent weekly platinum-based
chemotherapy following aggressive cytoreduction has been
shown to be of benefit. It however remains unclear whether
patients with de novo primary squamous cell cancer of the
ovary would benefit as much from similar adjuvant therapy. 
To conclude primary squamous cell cancers arising
in the ovary is an extremely rare entity, and has not
previously been described in patients of Southeast Asian
heritage. In the absence of well designed trials, and based on
the existing albeit sparse data, the primary management
approach at present is surgical debulking, akin to the
principles underlying the management of ovarian
adenocarcinoma. Combination chemotherapy with newer
drugs has shown some benefit and pelvic radiotherapy may
have a role to play for local control. However, in the
absence of quality data, except for the very early stages of
presentation, a role for adjuvant therapy is at present
unclear. 
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Abstract
Primary Cutaneous lymphomas of B cell origin are
rare, there remains a controversy in truly classifying these
lymphomas and an updated EORTC classification divides
them on the basis of their  distinct histopthological grounds
rather than on the basis of their anatomic location as in WHO
classification, while the new WHO- EORTC joint
classification maintains some characteristics of both systems,
We report an elderly gentleman who primarily had a typical  
Leg dominant Cutaneous lymphoma of B cell origin
uniquely with involvement of nasal Sinusues , bearing the
Immunohistochemical staining features of " Cutaneous
lymphoma - Leg Type" befitting the new joint WHO-EORTC
classification of Cutaneous B cell Lymphoma.
Introduction
Cutaneous lymphomas are uncommon skin tumours,
with skin being either the primary site for the origin of the
tumour or more often the secondary site. Approximately
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65% of the cutaneous lymphomas are T cell in origin and
only 20-25% are thought to originate from the B cell, with
majority of these being diffuse large B cell type.1 Most of
the primary cutaneous lymphomas have an indolent
behaviour.2
Primary Cutaneous  B-cell lymphoma (PCBCL) as
an entity was introduced in 1990s to characterize a group of
lymphoproliferative disorders characterized by clonal
proliferation of  B lymphocytes primarily  involving the
skin.3 According to the Revised European and American
Classification of Lymphoid Neoplasms  (REAL) / World
Health Organization  (WHO) classification the Non
Hodgkin's lymphomas, lymphomas which have large cell
morphology and diffuse growth pattern are designated as
diffuse large B cell lymphoma  (DLBCL).4 The European
Organization for Research and Treatment of Cancer
(EORTC) divided primary cutaneous  B-cell lymphomas
(PCBL)  in four groups, one of them being The Primary
cutaneous diffuse large B-cell lymphoma, 'leg type' 5; They
are a heterogeneous group of lymphomas that primarily
involve the skin but may have variable clinical,
histopathologic, and immunologic phenotypes.
We are reporting a case of an elderly patient, with
Primary Cutaneous Large B cell lymphoma (PCLBCL)
rather unique in having primarily the involvement of both
lower limbs along with simultaneous involvement of
paranasal sinuses extending to involve the inferior orbital
area.
Case Report
A 70 year old gentleman, presented in April 2007
with a history of  painless skin nodules that developed over
two months. Initially these nodules were small and on the
shin of left leg but gradually they progressed to involve the
right leg, right arm and left hand and right side of nose. The
Figure 1: Appearance of the lesions on face and legs. Figure: 3 CT scan of paranasal sinuses showing the extent of the lesion in paranasal sinuses.
LCA
Figure 2. characterstic Immunocytochemical Stains and H & E stains: showing positivity to LCA,
CD20, BCL2  and MUM 1, CD3 is characteristically Not stained.
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skin covering these nodules first became black followed by
development of blisters with serous discharge which finally
became thick and crusted  (Figure 1).
On examination there were bilateral blistering lesion
at legs and on the  dorsum of the right foot, crusted  with
mild serous discharge on bilateral shins, skin nodules on
right side of nose, right and left forearm and swollen left
middle finger. Rest of the systemic examination was
unremarkable, his overall ECOG performance status was 2.
Laboratory investigations at the time of presentation
were: Blood Urea Nitrogen: 19mg/dl,   serum Creatinine:
0.9mg/dl,  total Billirubin: 1.0 mg/dl, Gamma Glutamine
transferease : 11 IU/l,  Alanine Aminotransferase:  9  IU/l,
Alkaline Phosphatase: 78 IU/l, serum  Albumin: 2.7 mg/dl,
serum Calcium: 7.6 mg/dl, serum Lactic
Dehydrogenase:1373 I.U/l. Complete blood counts were
Hb: 9.0 gm/dl, WBC: 7.1 x 109/l and Platelets: 262x 109/dl.
Biopsy specimen of leg lesions gave the diagnosis of
diffuse large B cell lymphoma, with the
immunohistochemical stains being positive for LCA, CD20,
CD79,  Bcl-2, Bcl-6, MiB 1,  MUM-1  and characteristically
negative for CD3 (Figure 2), (Figure 3).
CT scans of paranasal sinuses, chest and abdomen
showed an enhancing soft tissue mass involving nasal
cavity, paranasal sinuses, nasopharynx on right side with
orbital extension and abdominal lymphadenopathy.
Discussion
Primary B cell Lymphoma of the  leg, which was
identified as a distinct  entity in the EORTC classification,
has now been incorporated in the new WHO-EORTC
classification of cutaneous B cell Lymphomas  as  'Primary
cutaneous  large B cell lymphoma, Leg Type',  ending the
longstanding controversy of placement and categorization
of the primary cutaneous B cell Lymphomas.6 The sub
classification of PCBCL is now made on morphological
features rather than anatomic site of presence and this is
important to remember, as the type in question is apt to
express Bcl-2, MUM-1, however and interestingly
expression of the said immophenotypic markers was not
associated with worse prognosis, as opposed to other types
of Cutaneous B cell lymphomas namely follicular
Cutaneous B cell lymphoma (PCFCLs).7
There however is a growing consensus that the
primary cutaneous DLBCL of leg is distinct in its behaviour as
opposed to the DLBCL occurring at the other sites in that
these patients are of older age group, more frequently females,
have a short duration of skin lesion before diagnosis.2,8
In a European multi centre study of 145 patients with
primary cutaneous DLBCL, round-cell morphology,
location on the leg, and multiple skin lesions at diagnosis
were found to be independent adverse prognostic factors
and these neoplasms are highly sensitive to radiotherapy9
and hence, it is the treatment of choice for localized disease
at presentation or relapse. Combination chemotherapy with
Cyclophosphomide, vincristine, Adriamycin and prednisone
(CHOP), with or without addition of Rituximab, is preferred
in patients with the tumour involving the leg, multiple skin
lesions or with systemic involvement.1,9
Our case is interesting in being a rare,
histopathologicaly fitting the new WHO-EORTC
classification of 'Primary Cutaneous diffuse large B-cell
lymphoma, leg type' and with clinical involvement of  Para
nasal sinuses, as for  primary Cutaneous lymphomas it's
very unusual to involve other organ sites. The patient was
managed in line of the recommended guidelines and  he
responded well to the treatment. This case reminds the
practicing physicians of diversity with which lymphoma
can present.
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